BIOCAD presents results of clinical trial showing netakimab decreases disease activity and reduces skin manifestation of psoriatic arthritis through 24 weeks of therapy. The treatment was well-tolerated, with significant improvement in skin manifestations and quality of life.
Prolgolimab, a Russian original PD-1 inhibitor, has been approved for the treatment of advanced melanoma. The drug demonstrated significant antitumor activity and manageable safety in a phase II study, with 42 out of 126 patients experiencing an objective response.
BIOCAD announces plans to introduce netakimab and progolimab, two original monoclonal antibody-based drugs, to the European market. The company has already received permission to conduct clinical trials in Europe for these innovative treatments.